ABVC Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 116578 min ago

@ $1.300

Išleistas: 8 vas. 2024 @ 20:07

Grąža: 5.77%

Ankstesnis signalas: vas. 7 - 16:30

Ankstesnis signalas: Pardavimas

Grąža: -7.80 %

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 20:02):

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States...

Stats
Šios dienos apimtis	1.53M
Vidutinė apimtis	1.09M
Rinkos kapitalizacija	14.52M
EPS	$0 ( 2024-03-29 )
Kita pelno data	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.570
ATR14	$0.00700 (0.51%)

Insider Trading

Date	Person	Action	type
2022-05-20	Jiang Shuling	Buy	Common Stock
2021-08-02	An Chihliang	Sell	Common Stock
2021-08-02	Sakamoto Norimi	Buy
2021-08-02	Odaira Yoshinobu	Sell	Common Stock
2021-08-02	Jiang Tsung Shann	Buy	Common Stock

INSIDER POWER
0.00
Last 77 transactions
Buy: 22 119 096 \| Sell: 9 170 000

Tūris Koreliacija

Ilgas: -0.20 (neutral)

Trumpas: -0.33 (neutral)

Signal:(43.212) Neutral

AMERICAN BRIVISION Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

AMERICAN BRIVISION Koreliacija - Valiuta/Žaliavos

-0.78
( moderate negative )

-0.70
( moderate negative )

0.00
( neutral )

-0.86
( strong negative )

0.76
( moderate )

AMERICAN BRIVISION Finansinės ataskaitos

Annual	2023
Pajamos:	$152 430
Bruto pelnas:	$-178 138 (-116.87 %)
EPS:	$-2.43

FY	2023
Pajamos:	$152 430
Bruto pelnas:	$-178 138 (-116.87 %)
EPS:	$-2.43

FY	2022
Pajamos:	$969 783
Bruto pelnas:	$683 368 (70.47 %)
EPS:	$-5.15

FY	2021
Pajamos:	$355 797
Bruto pelnas:	$350 711 (98.57 %)
EPS:	$-0.510

Financial Reports:

No articles found.

AMERICAN BRIVISION

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.